Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019460 | 0.74 | PDK1 (0.35) | NLRP3PDK1DPP4FAPDPP8 | |
| SCHEMBL3020879 | 0.74 | CHRM2 (0.33) | — | |
| SCHEMBL3013676 | 0.73 | PDK1 (0.34) | NLRP3PDK1SCN7ASCN5ASCN9A | |
| SCHEMBL3012596 | 0.71 | NLRP3 (0.33) | NLRP3PDK1OPRM1OPRD1OPRK1 | |
| SCHEMBL3020784 | 0.68 | CHRM2 (0.35) | — | |
| SCHEMBL3020386 | 0.63 | PDK1 (0.38) | NLRP3PDK1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL5998823 | 0.62 | PDK1 (0.36) | NLRP3PDK1 | |
| SCHEMBL3009748 | 0.60 | PDK1 (0.36) | NLRP3PDK1 | |
| SCHEMBL24578244 | 0.59 | CHRNB2 (0.59) | CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL20869642 | 0.59 | CHRNB2 (0.59) | CHRNB2CHRNA5CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | NLRP3 2931/4885PDK1 1868/4885SCN7A 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.